Return to CBI Antibody Core Home Page
  Return to Drosophila list
    Return to fruit fly ( Drosophila melanogaster ) list


fruit fly ( Drosophila melanogaster )
huntingtin


Links to multiple antibodies on this page for huntingtin:
htt
htt


Western result: +
control
htt
A1020b
(fragment)

N.A. kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (recombinant fusion protein containing a His tag). The negative control lane is the same except it contains ~50ng to 100 ng of a recombinant fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used.

Antibody Name/Abbreviation: htt
CBI Antibody Core Code: A1020b

"Lot" Number: 1 Position: 20 (1156-1175)
% Identical Homology of Target to Mouse Protein: 0%
Molecular Weight of GST-fusion: N.A. KDa

Target sequence used to make this antibody:
DNALSSQRQQQRRPNDAGTC






Antibody Name/Abbreviation: htt
CBI Antibody Core Code: A1020a

"Lot" Number: 2 Position: 100 (325-424)
% Identical Homology of Target to Mouse Protein: 0%
Molecular Weight of fusion protein: 25 KDa

Target sequence used to make this antibody:
SDGQCSQSLGQSLRQLLCNQQLQHNEYLRRRKSLKNQIFQ
LKNYEVATSQHQLEDEDENEDVDELVVGATAMQMKKNSNA
KLQQAKCREQQQHQHQQQLE






Sequence Name: huntingtin
Full name: huntingtin
UniGene Number: N.A.
Accession Number: N.A.
Source organism: fruit fly ( Drosophila melanogaster )
Full length size (aa): 3584
NCBI information page:

Full length sequence:
MDKSRSSAYDKFVGFVEQLRNTECSQKQKITCFQQIAECIMSPSLAGHIN
YAAHCGTATNVLLLFCEDVDSVVRMSAEENLNKILRSLEKTRVSRILMDL
YGEIKRNGNQRSLRICLNLFSYYAPQIKEKHIKWYAVRLLQCMTTISQRK
ETLLQETLCDFVKHFSRHIQQGLSDSESCKLFETFLDQISSDCAVKRRCS
AQNCMSLIENARNRSLMARHGVNKVMELLLTDQQANSVLGALGLLRLLLP
QLIRGYPGDSHEDSESLAGKKQQQQQTTTSDCRQIIEIYDYCLHLLSTQH
TANHAIINATLEVINGILQAVDAASDGQCSQSLGQSLRQLLCNQQLQHNE
YLRRRKSLKNQIFQLKNYEVATSQHQLEDEDENEDVDELVVGATAMQMKK
NSNAKLQQAKCREQQQHQHQQQLEVDNSSLGINAGEDAPTEAPSSVADEG
GEPESTKLRCHIRNAARSISECVASDEDKQGQGHRQQRDEDGVVVAEDDD
DDDDDDDDDDDMELLSAECDDFTTLSQLNEQQQALSAALKLPTTTAASSG
GAATSQDDKLIDVDADVGGLPKPQHQSSLQNLLAGSDDKSQHLSDIDNES
FNSIDFDAEITIAGSKEQQQQHPPADDSVESGDATAIGTFFNNLLSHSNA
ASESVSKLFRQSSGSKSTPSKSASTPAPADKSDAISAASLTLSLTSLASS
NLEPPERQPLIAETPTPVEDSCSITASHTASTALMMDAPAVEVAASKPET
PQLRGTPNANPFLVENSPLRQTVVGRALITVKIGSILEQSLVYYTARLVA
ARFLLSGQAAGLQPDSISRVSIKSLSLAVIAQCVRLAPKILQLSLEISEQ
ELQLLEEATSQIGSGDSTQVSSPQSSDNSQVGGEKPPLDSSLVPTSLEEN
LLLLDIKDDHFGPSTCPAYLQSATPTLSRSADASVLLLEVGTTSSRSAKK
SEEMLSKSEIIESSYRPTVAVEDVPPLSMPPRPPKRTKSTRSRVGVLGTS
STTESSSPQSRQKLSDILLFHDHCDPILRGGVQQVVGNFLQSSGAGLFLD
LQRGLGLQHLLAILLKGFEDEIHTVVIQALNAFDKIFPNVVSKYLTEPPC
HYHAHQQQQQQQKEQQQQEQDNQKLEQDLQRHSSGQQKRSGQAQTFGQQT
FAKDQDNALSSQRQQQRRPNDAGTCANSSATDNDELLAALLNDFQLQSTG
MRQQPKNNSTDIGQSGNEPDLEPNPNAAVEPFCVFAISPKLLLSKLRLCH
HNKYWLVQNKYAEVISNLNYVLLRSYYANFRCAIDNKNSGARKQDSKWPP
MDASSVCHSVRDAEGEDIVCTYEAQFLAELLHLLGDDDARVREHAACCLC
RFIMQTARQDPSQDQGAGGGGGDDIEGNGNVNVETQQTNFNLLWDFFDYR
IFGSMSVTLRNLFRASSTIVPPLAELDALATSNSAPSYPDTGSTSGSSTS
TSASSGGSAAAVSAASAYFEASYGIGIAEGHVFALASASQRQIAQEEKVL
AKVLYRLTNKLMTLNDKNVQFGIIYALRLLLRHFNFVDYQQAWLEFNFVE
ICISYAYYNNATAADLGCQNDLIDVMGKLMAGAMLSSGEPNTAHLDFLLR
HSVKMLNIYYHLVTNQRPPTAGSQSGSSSSKQPKSELFAREQPAATLQAL
GYFAGDYVYMKLYNILRGANDSYKITINQEAGSLLICLLKTCLHAVSLCL
EGMASASPPELKLIEEILHYLTRLINYAPAECVACLRQLLKYLFAQNYAS
QVRLQPSAGIGGNGTGIGHHAAFMRPYFAAKGRGHGASSTLLPTINSKPA
VAVGSQRGAPTDARQPIDAGPLQDMGMLFVHGLQPPTPPAGDCVRLIKLF
EPMVIYCLTLFMKSNALVQAPILRLLSQLLDLNVTYSILDSKNVIFDQVL
SNMDLIEGGIDRNAFIMVPPMLRFLVQLTHKSDRQLITIPKIISITNNLL
ANGSVRVVALLALKTLSYELFFMHSQLEEALDTEGHNSGRDACQSPLSAA
PTPETREALLAQRRELDTQREVVLGMLEKFIEARPSQQVLALLLLFERSV
QQLDTPPYRSAQDADAVYGTLCRGLCSRQWRLHNAGDLRLLESCFRNNGN
HVLADSKRFLQLLQLFIEQGVGNFGDLALAMVMLSNVILKTEEIYLVNHI
KLYLKNNPTAERRLQALMPSSPSAAPHWQDEAPSTSSAAAAARAAAASFS
AGRSSISEINYFAKVLCEKLLACLEVLLGLEPSSSSHAYCQLTGRFMDAL
LNVCCRSRHKDALQSVFRLVLAESEFLCKYYSLLLMSAAGLVGSHSLDAV
LLACLRLVLAMRLEEPVALLEQAAQLPLKTNLQRALLREVCRASAGCDWS
AQQVRRLFEGRYLNFLIADHLEFICELCQERPECGSLLQVALFRNAHRLS
RQSVRIVLRLLGRLCEPAEREASGDVGSDADPTLQAMQLLSRLHQLYEGE
RSLQLPIERMARRLSAQSGQPARNVIYERLVEGDLAGGEDQDALRTLLLK
DLECRQDNETATPSRIIDESWLFAQLIKFATQHADAPQQQKQLMLLLLEI
QSEPKLQRLLRSLGTEHEAKLLRHAIAGSLAAMMSAFRQKCIQHAPHINY
MQPTPLARVSCALLMSRVASTEATKCRNPPTGEQLDVARAVGALMACIRN
AEQTALIYIDARLMEKFVVEHLLRREHLPQLLAYLGWLAGAAKQILAMPT
RQESEQDALGVLLATVNTLLQQPRVWRELNASSDPSLRCELLDLLDSVAR
CILQDTIFYRRHRRDRNKAKGPAPQAIFLAKLIETQIEIESLASGRVLAG
VEEARLQFAGQDLARFQVALSLVTSIGISLLRTHQFYAYAVTPHELIQQP
GDQQQEQQADGKLPSIPVDSLSDVDVLRQFVKRLSIFGFTTRQQFEEYFM
TCLLLINKLYDEHMVDQQEQFQIKQVCLQAILELLMTYKTFPIVGMANGQ
FHHTTRWQRITCDSISLKKLHKVQLLVDACNVFYQPNLERQLAYDNVIGT
RTFAPNQYDLNFSWAQMEDQAAAGVGVGVGVGLSGGEQANTADIKQSCDA
DVPDMAMRNYRHFTQLSGIDFRSSTQLVFDVLQQMIELNHILVLPNLVKF
CEICESRDHIKWIKERCLKLQEQVAMDDTISHQHIIYLLCRSQALLIPSL
GELQVLCSLIGNVYLKSTHSFIRIATLQGLLCLLECCSKTNTTMGRLSEE
LALLRSLIVGYINRHGIIDESPLPFSVEHTKLVWTLNYSLIEWTSKFVPQ
CHLLSNTIIAANNFLKTTADEELYLCVLHGLERMVVNSGVPPPGIQPTGK
DAAAGEPGAEGSKAGVGVVVTPQMRHKIEKLALELLKMENEKFSIPALKL
LLSCMYVGSAAQLENTELSNGIVQDDPEIIAQQNDKVDILLHCIKSSTRD
AAWIYGQVLCQIIRDLVPPNEILTKVIKEFLAINHPHCDVIAMIVYQVFR
SAIDSSYLQMLQDWLICTLPTFLDQPEQQGVWGLSVIFLSASINLHLIKL
FPLVLGIGASNSAAAATTATTATTEAEAAAPAMARKLGQHEIALFVTAAQ
DFHAKLSGEQRQRFREAFGSFKRSQVYGRMLQCL





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.